Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
47.32 USD
↘ 1.25 (2.57%)AT CLOSE (11:59 AM EDT)
47.30
↗ 0.51 (1.08%)
POST MARKET (AS OF 05:43 PM EDT)
Post Market
AS OF 05:43 PM EDT
47.30
↗ 0.51 (1.08%)
🟢Market: OPEN
Open?$47.98
High?$48.39
Low?$47.28
Prev. Close?$48.57
Volume?2.8M
Avg. Volume?3.4M
VWAP?$47.59
Rel. Volume?0.81x
Bid / Ask
Bid?$45.59 × 100
Ask?$50.03 × 100
Spread?$4.44
Midpoint?$47.81
Valuation & Ratios
Market Cap?20.8B
Shares Out?428.4M
Float?406.4M
Float %?94.9%
P/E Ratio?26.99
P/B Ratio?3.21
EPS?$1.80
Dividend?3.52%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.40Strong
Quick Ratio?2.40Strong
Cash Ratio?0.97Adequate
Debt/Equity?1.40Moderate
ValuationRICHLY VALUED
Score
47/100
P/E?
27.0FAIR▾
P/B?
3.21FAIR▾
P/S?
8.75HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
20.3HIGH▾
EV/Sales?
12.30HIGH▾
Returns & Efficiency
ROE?
11.9%FAIR▾
ROA?
3.9%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$29.3B
Related Companies
Loading...
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees
100
Market Cap
20.8B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
MarketsMoversWatchlist